BIOGENERA SpA has officially signed an agreement with CVBF (Consortium for Biological and Pharmacological Evaluations) to monitor and execute the phase I clinical trial of the new drug BGA002, intended for the treatment of aggressive pediatric cancers associated with alterations in the MYCN tumor gene.
BIOGENERA has chosen CVBF as its Clinical CRO (Contract Research Organization) because of its years of experience in developing new biologic drugs for pediatric diseases. CVBF has successfully collaborated with numerous sponsors, research centers internationally in the pharmaceutical and biotechnology fields.
CVBF is part of several European research networks for knowledge transfer and scientific excellence. Key collaborations include TEDDY European Network of Excellence for Paediatric Research, European CRO Federation (EUCROF), and iCAN Network (International Children’s Advisory Network), all of which are committed to promoting the development of safe and effective new drugs for children.
The primary goal of the collaboration between BIOGENERA and CVBF is to initiate clinical phase I of the anti-cancer drug BGA002 in early 2025, also taking advantage of the benefits of the Orphan Drug designation obtained from both the European Medicines Agency and the U.S. FDA.
CVBF will support BIOGENERA in conducting the study not only at Italian clinical centers of excellence, but also at the European level, with the intention of completing it quickly.
As a reminder, there are only a few days left (until Friday, June 28) to invest in BIOGENERA’s campaign on Mamacrowd, with numerous benefits associated with the Paris listing.
Don’t miss the opportunity to participate in creating new targeted, effective and safe treatments for cancers and other serious diseases.
Find out here: https://mamacrowd.com/it/project/biogenera
